Company intelligence / Profile preview

Jiangsu Tuohong Kangheng Pharmaceutical

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Jiangsu Tuohong Kangheng Pharmaceutical is advancing human umbilical cord mesenchymal stem cell therapy, with phase 3 studies for Crohn disease and perianal fistula due to Crohn’s disease underway; additional studies for radiation proctitis and radiation-induced rectal injury have reached phase 2 and phase 1, with positive clinical results disclosed for their MSC therapy.

Therapeutic areas: Gastroenterology
Modalities: Mesenchymal stem cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Jiangsu Tuohong Kangheng Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Tuohong Kangheng Pharmaceutical.

Explore the full profile